Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients

Схожие документы

• Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib
  по: CHEN, YUH-MIN, et al.
  Опубликовано: (2011)
• Impact of severe acute respiratory syndrome on the status of lung cancer chemotherapy patients and a correlation of the signs and symptoms
  по: Chen, Yuh-Min, et al.
  Опубликовано: (2004)
• Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations
  по: WU, WEN-SHUO, et al.
  Опубликовано: (2012)
• Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung
  по: HUANG, CHU-YUN, et al.
  Опубликовано: (2014)
• An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
  по: Wu, Shang-Gin, et al.
  Опубликовано: (2020)